ArticleThe Journal of infectious diseases2023
Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years.
Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 67 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"Assessment of the Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations in Ile-de-France Region in France""
Evaluation of Demographic, Clinical, and Healthcare Utilization Characteristics of Respiratory Syncytial Virus (RSV) Positive Cases Under 5 Years Presenting to Pediatric Emergency Departments in Türkiye: A Multicenter, Prospective Observational Study (TRUST-RSV)
Who cites it
67 citing papers in PubMed, 6 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Burden and Characteristics of Respiratory Syncytial Virus-Associated Bronchiolitis in Hospitalized Infants in Italy: A Systematic Review.Immunity, inflammation and disease · 2026Pooled it
- Maternal RSV vaccine: a systematic review and meta-analysis of immunogenicity and perinatal safety.Immunologic research · 2025Pooled it
- Burden of RSV in Young Children in High-Income Countries: Incidence Estimates From a Multilevel Meta-Analysis in Primary and Emergency Care.Influenza and other respiratory viruses · 2025Pooled it
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.The Cochrane database of systematic reviews · 2025Pooled it
- Prevalence of respiratory viruses in children with respiratory tract infections during the COVID-19 pandemic era: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.BMC infectious diseases · 2024Pooled it
- Strategies used to improve immunization coverage of nirsevimab in an autonomous community in Spain.Human vaccines & immunotherapeutics · 2026Article
- Health and Economic Impact of Seasonal Maternal Vaccination With Bivalent Respiratory Syncytial Virus Prefusion F Vaccine in Belgium.The Pediatric infectious disease journal · 2026Article
- Observational
- Proposed Conceptual and Experience-Based Framework for Reaching an Optimal Vaccine Launch Strategy.Vaccines · 2026Article
- Economic Burden of RSV-Associated Hospitalizations in Switzerland: A Nationwide Analysis (2017-2023).Healthcare (Basel, Switzerland) · 2026Article
- Bacterial-Derived Immunomodulators as a Preventive Strategy for Viral Respiratory Tract Infections and Associated Wheezing or Asthma in Children: A Targeted Narrative Review.Children (Basel, Switzerland) · 2026Review
- Burden of Hospitalized Respiratory Syncytial Virus in Children in Sweden: A Population-based Case-cohort Study (2006-2023).The Pediatric infectious disease journal · 2026Article
- Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis.The Lancet regional health. Europe · 2026Article
- What Form of RSV Protection Do Women Prefer: Maternal Vaccination or Infant Immunisation? A Cross-Sectional Survey in Europe.Vaccines · 2026Article
- Comparison of Hospitalization Rates and Clinical Features Between Boys and Girls With Respiratory Syncytial Virus Infection.Influenza and other respiratory viruses · 2026Article
- Cost-effectiveness of maternal vaccine and/or monoclonal antibody strategies against respiratory syncytial virus in Belgian infants.NPJ vaccines · 2026Article
- Stratify severe risk in children with respiratory syncytial virus pneumonia-A retrospective study based on machine learning and SHAP interpretation.Frontiers in pediatrics · 2026Article
- SARS-CoV-2, Influenza and Other Respiratory Viruses: Epidemiology, Burden of Disease, and Preventive Measures.Vaccines · 2025Article
- Hospital burden of Respiratory Syncytial Virus in children in Spain (2016-2022): A retrospective study.Human vaccines & immunotherapeutics · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 9 countries.
Funding
Abstract
backgroundNo overall estimate of respiratory syncytial virus (RSV)-associated hospitalizations in children aged under 5 years has been published for the European Union (EU). We aimed to estimate the RSV hospitalization burden in children aged under 5 years in EU countries and Norway, by age group.
methodsWe collated national RSV-associated hospitalization estimates calculated using linear regression models via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands, and Scotland, 2006-2018. Additional estimates were obtained from a systematic review. Using multiple imputation and nearest neighbor matching methods, we estimated overall RSV-associated hospitalizations and rates in the EU.
resultsAdditional estimates for 2 countries (France and Spain) were found in the literature. In the EU, an average of 245 244 (95% confidence interval [CI], 224 688-265 799) yearly hospital admissions with a respiratory infection per year were associated with RSV in children aged under 5 years, with most cases occurring among children aged under 1 year (75%). Infants aged under 2 months represented the most affected group (71.6 per 1000 children; 95% CI, 66.6-76.6).
conclusionsOur findings will help support decisions regarding prevention efforts and represent an important benchmark to understand changes in the RSV burden following the introduction of RSV immunization programs in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.